OncLive - The European Commission has approved single-agent olaparib as a maintenance treatment for adult patients with germline BRCA1/2-mutant metastatic pancreatic adenocarcinoma who have not progressed...
Tweets from: OncLive
OncLive - Investigators are working on a new generation of therapies that activate CD40, an immune checkpoint that helps promote an antitumor response by boosting T-cell–stimulatory...
OncLive - OncLive serves as a connection to everything oncology, including interviews and videos from thought leaders and cutting edge articles and...
OncLive - A panel of experts in chronic myeloid leukemia share insight on how to optimally approach treatment based on patient...
Yale Cancer Center Study Validates Combination Therapy for Aggressive Endometrial Cancer
posted 3 hours
Shared 0 times
OncLive - Yale Cancer Center scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive...
Long-Term KEYNOTE-426 Data Support Pembrolizumab/Axitinib as Frontline Standard in Advanced RCC
posted 4 hours
Shared 0 times
OncLive - Pembrolizumab plus axitinib continued to significantly improve efficacy over sunitinib in patients with previously untreated metastatic renal cell carcinoma, according to updated results from...
FDA Issues Complete Response Letter for Pembrolizumab/Lenvatinib in First-Line HCC
posted 5 hours
Shared 0 times
OncLive - The FDA has issued a complete response letter to Merck and Eisai stating that it will not approve the applications that are seeking the...
Systemic Therapies Improve Breast Cancer With Brain Metastases Management
posted 6 hours
Shared 0 times
OncLive - Kamran A. Ahmed, MD, discusses the evolution of treatment for patients with breast cancer brain metastases, recent pivotal findings that have significantly improved survival...
COVID-19 Blood Clotting Cause Identified in Study Led by Yale Cancer Center Researchers
posted 7 hours
Shared 0 times
OncLive - One of the major mysteries in treating patients with COVID-19 is the frequent development of blood clots that can subsequently damage their organs and...
OncLive - Immunotherapy and BRAF plus MEK inhibition are the key players in the treatment of patients with melanoma, Michael Postow, MD, said in a presentation...
.@EU_Commission has approved single-agent olaparib as a maintenance treatment for germline BRCA1/2-mutant metastatic pancreatic adenocarcinoma. @UChicagoMed #pancsm https://t.co/yUNPw4TkEL https://t.co/yUNPw4TkEL